164 related articles for article (PubMed ID: 31787238)
1. Novel activating KRAS mutation candidates in lung adenocarcinoma.
Abe J; Tanuma N; Nomura M; Ito S; Kasugai I; Sato I; Tamai K; Mochizuki M; Yamaguchi K; Shima H; Okada Y; Yasuda J
Biochem Biophys Res Commun; 2020 Feb; 522(3):690-696. PubMed ID: 31787238
[TBL] [Abstract][Full Text] [Related]
2.
Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
[No Abstract] [Full Text] [Related]
3. Oncogenic KRAS Sensitizes Lung Adenocarcinoma to GSK-J4-Induced Metabolic and Oxidative Stress.
Hong BJ; Park WY; Kim HR; Moon JW; Lee HY; Park JH; Kim SK; Oh Y; Roe JS; Kim MY
Cancer Res; 2019 Nov; 79(22):5849-5859. PubMed ID: 31506334
[TBL] [Abstract][Full Text] [Related]
4. YTHDF1 Promotes Cyclin B1 Translation through m
Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
[TBL] [Abstract][Full Text] [Related]
5. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
[TBL] [Abstract][Full Text] [Related]
6. G48A, a New KRAS Mutation Found in Lung Adenocarcinoma.
Marabese M; Caiola E; Garassino MC; Rastelli G; Settanni G; Brugnara S; Broggini M; Ganzinelli M
J Thorac Oncol; 2016 Jul; 11(7):1170-5. PubMed ID: 27058911
[TBL] [Abstract][Full Text] [Related]
7. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
[TBL] [Abstract][Full Text] [Related]
8. In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma.
Ambrogio C; Barbacid M; Santamaría D
Oncogene; 2017 Apr; 36(16):2309-2318. PubMed ID: 27775074
[TBL] [Abstract][Full Text] [Related]
9. IκB Kinase α Is Required for Development and Progression of
Vreka M; Lilis I; Papageorgopoulou M; Giotopoulou GA; Lianou M; Giopanou I; Kanellakis NI; Spella M; Agalioti T; Armenis V; Goldmann T; Marwitz S; Yull FE; Blackwell TS; Pasparakis M; Marazioti A; Stathopoulos GT
Cancer Res; 2018 Jun; 78(11):2939-2951. PubMed ID: 29588349
[TBL] [Abstract][Full Text] [Related]
10. Requirement for MUC5AC in KRAS-dependent lung carcinogenesis.
Bauer AK; Umer M; Richardson VL; Cumpian AM; Harder AQ; Khosravi N; Azzegagh Z; Hara NM; Ehre C; Mohebnasab M; Caetano MS; Merrick DT; van Bokhoven A; Wistuba II; Kadara H; Dickey BF; Velmurugan K; Mann PR; Lu X; Barón AE; Evans CM; Moghaddam SJ
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089720
[TBL] [Abstract][Full Text] [Related]
11. Osteopontin drives KRAS-mutant lung adenocarcinoma.
Giopanou I; Kanellakis NI; Giannou AD; Lilis I; Marazioti A; Spella M; Papaleonidopoulos V; Simoes DCM; Zazara DE; Agalioti T; Moschos C; Magkouta S; Kalomenidis I; Panoutsakopoulou V; Lamort AS; Stathopoulos GT; Psallidas I
Carcinogenesis; 2020 Aug; 41(8):1134-1144. PubMed ID: 31740923
[TBL] [Abstract][Full Text] [Related]
12. Low-Coverage Whole Genome Sequencing Using Laser Capture Microscopy with Combined Digital Droplet PCR: An Effective Tool to Study Copy Number and Kras Mutations in Early Lung Adenocarcinoma Development.
Mickler EA; Zhou H; Phang TL; Geraci MW; Stearman RS; Sears CR
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769463
[TBL] [Abstract][Full Text] [Related]
13. The ERBB network facilitates KRAS-driven lung tumorigenesis.
Kruspig B; Monteverde T; Neidler S; Hock A; Kerr E; Nixon C; Clark W; Hedley A; Laing S; Coffelt SB; Le Quesne J; Dick C; Vousden KH; Martins CP; Murphy DJ
Sci Transl Med; 2018 Jun; 10(446):. PubMed ID: 29925636
[TBL] [Abstract][Full Text] [Related]
14. Notch1 Deficiency Induces Tumor Cell Accumulation Inside the Bronchiolar Lumen and Increases TAZ Expression in an Autochthonous
Meder L; Florin A; Ozretić L; Nill M; Koker M; Meemboor S; Radtke F; Diehl L; Ullrich RT; Odenthal M; Büttner R; Heukamp LC
Pathol Oncol Res; 2021; 27():596522. PubMed ID: 34257546
[No Abstract] [Full Text] [Related]
15. [Therapeutic possibilities in KRAS-mutant lung adenocarcinoma].
Radeczky P; Ghimessy Á; Berta J; László V; Hegedűs B; Rényi-Vámos F; Fillinger J; Megyesfalvi Z; Döme B
Magy Onkol; 2020 Sep; 64(3):231-244. PubMed ID: 33196710
[TBL] [Abstract][Full Text] [Related]
16. REG4 is an indicator for KRAS mutant lung adenocarcinoma with TTF-1 low expression.
Sun S; Hu Z; Huang S; Ye X; Wang J; Chang J; Wu X; Wang Q; Zhang L; Hu X; Yu H
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2273-2283. PubMed ID: 31428934
[TBL] [Abstract][Full Text] [Related]
17. KRAS mutation-positive bronchial surface epithelium (BSE)-type lung adenocarcinoma with strong expression of TTF-1: a case providing a further insight as for the role of TTF-1 in the oncogenesis.
Takanashi Y; Tajima S; Hayakawa T; Neyatani H; Funai K
Int J Clin Exp Pathol; 2015; 8(11):15338-43. PubMed ID: 26823891
[TBL] [Abstract][Full Text] [Related]
18. Metachronous primary lung adenocarcinomas harboring distinct KRAS mutations.
Hu Y; Ren S; Chen C; Liang Q; Yu F; Liu W
Thorac Cancer; 2020 Jul; 11(7):2018-2022. PubMed ID: 32415761
[TBL] [Abstract][Full Text] [Related]
19. VICKZ1 enhances tumor progression and metastasis in lung adenocarcinomas in mice.
Rosenfeld YB; Krumbein M; Yeffet A; Schiffmann N; Mishalian I; Pikarsky E; Oberman F; Fridlender Z; Yisraeli JK
Oncogene; 2019 May; 38(21):4169-4181. PubMed ID: 30700831
[TBL] [Abstract][Full Text] [Related]
20. The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol.
Albayrak G; Korkmaz FD; Tozcu D; Dogan Turacli I
J Cell Biochem; 2019 Jun; 120(6):10564-10571. PubMed ID: 30628735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
